The De La Cruz acne treatment, which is available on Amazon, is a 10-minute wash-off mask that targets a variety of acne ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adultsCosibelimab PDUFA goal date of December 28 for ...

Tarsus is studying TP-04 for the treatment of papulopustular rosacea (PPR). About TP-05 TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that selectively ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new ...

A doctor has offered guidance on managing a common skin condition that often worsens during the colder months. Sharing advice ...

According to the NHS, rosacea is a long-term skin condition that can cause redness, dry skin, and swelling, and it can be ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. In ...

SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical ...